BriaCell reports preclinical data at 2024 AACR meeting

BriaCell Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-OTS+ and Bria-PROS+, in a poster session during the 2024 American Association for Cancer Research, AACR, Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA. “Our data demonstrates enhancement of immune responses and expanded mechanisms of action of the Bria-OTS platform,” commented Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “We anticipate that our novel immunotherapeutic platform will provide potent and long-lasting anti-cancer activity in cancer patients. We view our technology as a significant scientific advancement in the field of oncology and personalized immunotherapy.”